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Arachidonic acid (AA) is metabolized to diverse bioactive lipid mediators. Whereas the 5-lipoxygenase-
activating protein (FLAP) facilitates AA conversion by 5-lipoxygenase (5-LOX) to pro-inflammatory 
leukotrienes (LTs), the soluble epoxide hydrolase (sEH) degrades anti-inflammatory epoxyeicosatrienoic 
acids (EETs). Accordingly, dual FLAP/sEH inhibition might be advantageous drugs for intervention of 
inflammation. We present the in vivo pharmacological profile and efficiency of N-[4-(benzothiazol-2-
ylmethoxy)-2-methylphenyl]-N′-(3,4-dichlorophenyl)urea (diflapolin) that dually targets FLAP and sEH. 
Diflapolin inhibited 5-LOX product formation in intact human monocytes and neutrophils with IC50 = 30 
and 170 nM, respectively, and suppressed the activity of isolated sEH (IC50 = 20 nM). Characteristic for 
FLAP inhibitors, diflapolin (I) failed to inhibit isolated 5-LOX, (II) blocked 5-LOX product formation in 
HEK cells only when 5-LOX/FLAP was co-expressed, (III) lost potency in intact cells when exogenous 
AA was supplied, and (IV) prevented 5-LOX/FLAP complex assembly in leukocytes. Diflapolin showed 
target specificity, as other enzymes related to AA metabolism (i.e., COX1/2, 12/15-LOX, LTA4H, LTC4S, 
mPGES1, and cPLA2) were not inhibited. In the zymosan-induced mouse peritonitis model, diflapolin 
impaired vascular permeability, inhibited cysteinyl-LTs and LTB4 formation, and suppressed neutrophil 
infiltration. Diflapolin is a highly active dual FLAP/sEH inhibitor in vitro and in vivo with target specificity 
to treat inflammation-related diseases.
The arachidonic acid (AA) cascade plays a central role in the biosynthesis of lipid mediators (LMs) with 
pro-inflammatory but also anti-inflammatory properties1. In mammalian cells, AA is released from phos-
pholipids by cytosolic phospholipase A2 (cPLA2) upon stimulation. Liberated AA can be converted via three 
different pathways to bioactive LMs: cyclooxygenases (COXs) catalyze the initial step in the formation of 
inflammation-initiating prostaglandins (PGs) and thromboxane (TX), whereas lipoxygenases (LOXs) form 
hydroperoxyeicosatetra enoic acids (HPETEs), leukotrienes (LTs), and lipoxins (LXs)2. Moreover, AA is trans-
formed by cytochrome P450 enzymes to monohydroxyeicosatetraenoic acids (HETEs) and epoxyeicosatrienoic 
acids (EETs)3, 4. EETs possess anti-inflammatory properties and are degraded by soluble epoxide hydrolase (sEH) 
to the corresponding diols (dihydroxyeicosatrienoic acids (DiHETrEs)) with associated loss of beneficial effects.
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COX inhibitors that block PG and TX formation have been intensively studied and are widely used to treat 
pain and inflammation, albeit with frequent and severe side-effects5. Despite significant efforts in developing 
compounds that interfere with the other pathways of the AA cascade (e.g. 5-LOX), the respective candidates failed 
in clinical trials due to unpredicted side effects or lack of efficacy6. Targeting solely one pathway out of the AA 
cascade could be one reason for this issue7, which is well-known for shunting of AA towards the 5-LOX pathway 
due to inhibition of PG/TX formation by aspirin or other COX inhibitors8. Thus, compounds that selectively act 
on multiple targets (so-called designed multiple ligands – DML)9, 10 may be appropriate to suppress the biosyn-
thesis of pro-inflammatory LMs but maintain anti-inflammatory LMs. Such agents may be advantageous over 
single-interfering drugs and may represent a promising pharmacological approach for intervention with complex 
diseases as inflammation9, 11–14. We recently discovered ((N-[4-(benzothiazol-2-ylmethoxy)-2-methylphenyl]-N′-
(3,4-dichlorophenyl)urea; compound 5 in ref. 15) as the first dual inhibitor of 5-lipoxygenase-activating protein 
(FLAP) and sEH by using a pharmacophore-based virtual screening15. This compound is now designated dif-
lapolin. FLAP, a nuclear membrane integral protein16, 17 assists 5-LOX in LT biosynthesis, and FLAP inhibitors 
(e.g. MK886, BAY-X 1005) efficiently abolish LT formation in vitro and in vivo18, 19. sEH degrades EETs with 
anti-inflammatory and antihypertensive properties to DiHETrEs that are assumed to be pro-inflammatory with 
additional detrimental properties20. Therefore, sEH inhibition is not only elevating EET levels, it rather stabi-
lizes epoxy-fatty acids with favorable actions. It was recently reported that co-administration of a sEH inhibitor 
with a FLAP inhibitor enhanced the anti-inflammatory activities in a murine model21, whereas sole inhibition of 
sEH lead to albuminuria22. These data support the development of dual FLAP/sEH inhibitors to achieve better 
therapeutic effects due to simultaneous suppression of pro-inflammatory LTs and DiHETrEs but maintaining 
anti-inflammatory EETs. Here, we present the molecular pharmacological profile and the effectiveness of the first 
dual FLAP/sEH inhibitor diflapolin15 using cell-free and cell-based analysis of biosynthetic pathways of the AA 
cascade as well as animal models of inflammation. We find that diflapolin is target-specific for sEH and FLAP 
with strong potencies and represents a highly effective anti-inflammatory compound.
Results
Diflapolin inhibits cellular 5-LOX product formation without affecting 5-LOX in cell-free 
assays. Based on a pharmacophore-based virtual screening campaign, diflapolin was identified as most 
potent agent out of 20 hit compounds that dually inhibited FLAP and sEH in simple screening assays15. The 
structure of diflapolin is composed of a urea moiety (present in the sEH reference inhibitor AUDA) potentially 
binding to sEH as a mimetic of epoxides, and an aromatic heterocyclic scaffold (benzothiazole, seemingly reflect-
ing the indole scaffold of the reference FLAP inhibitor MK886) that may primarily confer FLAP interference 
(Fig. 1a). We first aimed to investigate the interference of diflapolin with FLAP and thus with 5-LOX product 
biosynthesis in more detail. Since FLAP does apparently not possess any measurable enzyme activity that can be 
readily monitored in a cell-free assay, functional interference of a given compound with FLAP requires indirect 
analysis of 5-LOX activation and product formation in intact cells23. In intact monocytes and neutrophils from 
human peripheral blood stimulated with Ca2+-ionophore, diflapolin effectively inhibited the formation of LTB4 
and its isomers and of 5-H(p)ETE with IC50 values of 30 and 170 nM, respectively (Fig. 1b). In order to exclude 
direct inhibition of 5-LOX, diflapolin was analyzed against 5-LOX activity in cell-free assays. Diflapolin, up to 
10 µM, did not significantly inhibit the activity of isolated human recombinant 5-LOX (not shown) or of 5-LOX 
in homogenates of neutrophils and monocytes (Fig. 1b). The same pattern of interference with 5-LOX product 
formation was observed for the FLAP inhibitor MK886 (IC50 monocytes: ~3 nM, neutrophils: 10–14 nM; IC50 
5-LOX in cell-free assays: >10 µM, not shown), which is in agreement with the literature24. In contrast, the direct 
5-LOX inhibitor zileuton inhibited 5-LOX activity in the cell-based (monocytes, neutrophils) and cell-free assays 
about equally well (IC50 = 1.5 and 0.8 µM, respectively), as reported25. A typical feature of FLAP inhibitors is their 
loss of efficiency, when cells are stimulated for 5-LOX product formation in the presence of exogenous AA, since 
(I) FLAP inhibitors compete with AA binding within the active site of FLAP26, and (II) ample AA supply may 
circumvent the requirement of FLAP for cellular 5-LOX product formation27, 28. In both monocytes and neutro-
phils, increasing levels of AA (up to 60 µM) sequentially reduced the inhibitory potency of diflapolin and shifted 
the IC50 values from 30 and 170 nM, respectively, (no AA supplementation) to >10 µM (at 60 µM AA) (Fig. 1c/d). 
These data suggest that diflapolin binds in the fatty acid substrate (AA) pocket of FLAP.
To confirm the hypothesis that diflapolin acts as FLAP inhibitor, we studied suppression of 5-LOX product 
formation in stably transfected HEK293 cells that either express 5-LOX plus FLAP or 5-LOX alone. Note that 
induction of 5-LOX product formation in HEK293 cells requires supplementation of exogenous AA (regardless 
of FLAP)29 and we therefore stimulated the cells with A23187 plus 3 µM AA. Diflapolin strongly inhibited 5-LOX 
product formation in intact HEK293 cells expressing both 5-LOX and FLAP, whereas in HEK293 cells deficient 
in FLAP, 5-LOX product formation was hardly impaired by diflapolin (Fig. 1e). Together, these data show that dif-
lapolin inhibits 5-LOX product formation only when FLAP is operative supporting FLAP as target of diflapolin.
Diflapolin inhibits epoxide hydrolase activity of sEH without affecting the phosphatase activ-
ity. sEH is a bifunctional enzyme with a C-terminal epoxide hydrolase (EH) and an N-terminal phosphatase 
activity that operate independent from each other30. In a cell-free assay, diflapolin reduced the EH activity of 
human recombinant sEH with an IC50 of 20 nM (Fig. 2a), comparable to the activity of AUDA (IC50 = 69 nM), a 
well-recognized reference inhibitor of sEH31. sEH is constitutively expressed in the human liver cancer cell line 
HepG2 making it suitable as cell-based test system for evaluation of diflapolin for sEH inhibition in the cellular 
context. HepG2 cells were pre-treated with diflapolin and control inhibitors, and incubated with the sEH sub-
strate 14,15-EET. sEH activity was then analyzed by monitoring 14,15-DiHETrE formation using UPLC-MS/MS. 
Diflapolin as well as AUDA inhibited cellular sEH activity to ~50% at 1 µM (Fig. 2b). Further decrease at con-
centrations up to 10 µM could not be observed, probably due to EET degradation that was sEH-independent and 
www.nature.com/scientificreports/
3SCIenTIFIC RepoRts | 7: 9398  | DOI:10.1038/s41598-017-09795-w
potentially non-enzymatic, as recombinant sEH in the corresponding cell-free assay yielded comparable results 
(Fig. 2b). AUDA reduced the sEH activity in a comparable manner, whereas MK886 and SC57461A (LTA4-H 
inhibitor) had no impact on sEH in the cell-based sEH assay (Fig. 2c).
Next, we tested diflapolin against the phosphatase activity of sEH in a cell-free assay. Of interest, diflapolin 
failed to inhibit the phosphatase activity even at high concentrations (10 µM) (Fig. 2d). In order to demonstrate 
that diflapolin as a specific inhibitor of the hydrolase activity of sEH, its effect on LTA4-H was determined. LTA4-H 
hydrolyses the epoxide in LTA4 that is produced from AA by 5-LOX in a co-incubation experiment using isolated 
5-LOX and LTA4-H, where LTB4 is formed. Diflapolin failed to inhibit LTA4-H activity (i.e. LTB4 formation) up to 
10 µM, compared to the LTA4-H inhibitor SC57461A (IC50 of 0.1 µM against recombinant LTA4-H)32 that blocked 
LTB4 biosynthesis and shifted the conversion of LTA4 towards the non-enzymatically formed trans-isomers of 
LTB4 (Fig. 2e). AUDA (10 µM) showed the same pattern as diflapolin, whereas zileuton (3 µM) as a direct 5-LOX 
inhibitor reduced the formation of all LTB4 isomers (Fig. 2e), as expected due to reduced LTA4 formation.
Effects of diflapolin on other eicosanoid biosynthetic enzymes. We next investigated the impact of 
diflapolin on other enzymes within the AA cascade that are involved in the biosynthesis of various eicosanoids in 
addition to FLAP and sEH. Besides FLAP, the LTC4S and mPGES-1 belong to the membrane-associated proteins 
in eicosanoid and glutathione metabolism (MAPEG) family sharing high sequence and structure homology to 
FLAP33, 34. Potent FLAP inhibitors (like MK886 or BRP-187) inhibit the MAPEG family members LTC4S and 
mPGES-1 as well27, 35, 36. In contrast, diflapolin failed to inhibit LTC4S and mPGES-1 activity in cell-free assays up 
to 10 µM (Fig. 3a,b), which indicates a high target specificity of diflapolin among the MAPEGs. Also, diflapolin 
did not significantly inhibit the activities of COX-1 and -2 in cell-free assays (Fig. 3c), whereas the reference drug 
indomethacin blocked COX activities, as expected. The activities of other LOXs (i.e. 12-LOX and 15-LOX) in neu-
trophils incubated with A23187 and 20 µM AA were not inhibited by diflapolin. In contrast, 15-HETE formation 
Figure 1. Diflapolin inhibits cellular 5-LOX product formation by targeting FLAP. (a) Chemical structure of 
the dual FLAP/sEH inhibitor diflapolin, with potential pharmacophoric moieties of typical FLAP (MK886) 
and sEH (AUDA) inhibitors. (b) Inhibition of 5-LOX product formation in human monocytes and neutrophils 
and in corresponding cell homogenates. Cells were pre-incubated with diflapolin (or 0.1% DMSO as vehicle) 
for 15 min and stimulated with 2.5 µM Ca2+-ionophore A23187 for 10 min. Cell homogenates were pre-
incubated with diflapolin (or 0.1% DMSO) for 10 min at 4 °C, pre-warmed at 37 °C for 30 sec, and 20 µM AA 
plus 1 mM CaCl2 was added for another 10 min at 37 °C. 5-LOX products were analyzed by HPLC. (c,d) Effects 
of exogenous AA on the potency of diflapolin for inhibition of 5-LOX product formation in neutrophils (c) 
and monocytes (d). Cells were pre-treated by diflapolin (or 0.1% DMSO as vehicle) at 37 °C for 15 min, and 
subsequently activated by 2.5 µM Ca2+-ionophore A23187 plus the indicated concentrations of exogenous AA 
for another 10 min. (e) HEK293 cells expressing 5-LOX or 5-LOX and FLAP were pre-incubated with diflapolin 
and stimulated with 5 µM Ca2+-ionophore A23187 plus 3 µM AA for 10 min at 37 °C. 5-LOX products were 
analyzed by HPLC. Data, expressed as percentage of vehicle control (=100%), are given as means ± S.E.M, n = 3 
*p < 0.05; **p < 0.005; ***p < 0.001 vs. vehicle control (ANOVA + Bonferroni with logarithmized values).
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was concentration-dependently elevated (up to 200% of the vehicle control) (Fig. 3d). Since diflapolin was most 
potent in leukocytes to suppress 5-LOX product formation from endogenous AA but ineffective when high con-
centrations of exogenous AA were supplied, the compound could act at the level of AA release. However, in [3H] 
AA-pre-labelled neutrophils, diflapolin even at high concentrations (1 µM) did not inhibit the release of AA 
upon A23187-stimulation, as compared to the cPLA2 inhibitor RSC-3388 that suppressed AA liberation (Fig. 3e). 
Finally, detrimental effects on cellular viability could be excluded, as diflapolin (10 µM) did not affect the viability 
of monocytes in a MTT assay at 24 or 48 hrs, while staurosporine (3 µM, positive control) strongly impaired cell 
viability under these conditions (Fig. 3f). Taken together, diflapolin dually and strongly inhibits FLAP and sEH 
with target specificity as it did not interfere with other AA pathway-related enzymes (LTA4-H, COX-1/2, cPLA2, 
12/15-LOXs) and FLAP-related MAPEG enzymes such as mPGES1 and LTC4S.
Effects of diflapolin on 5-LOX subcellular redistribution and 5-LOX/FLAP complex assem-
bly. 5-LOX, a soluble cytosolic or intranuclear enzyme in resting leukocytes, translocates to the nuclear enve-
lope upon cell activation and co-localizes with FLAP at the nuclear membrane to form a tight LT biosynthetic 
complex37, 38. Immunofluorescence microscopy studies using human neutrophils or monocytes showed that 
neither diflapolin nor the FLAP inhibitor MK886 or the 5-LOX inhibitor zileuton prevented co-localization of 
5-LOX with FLAP (Fig. 4). However, diflapolin efficiently prevented the tight 5-LOX/FLAP complex assembly, 
Figure 2. Diflapolin inhibits epoxide hydrolase activity of sEH. (a) The epoxide hydrolase activity of human 
recombinant sEH was analyzed in fluorescence-based cell-free assay. Diflapolin, AUDA (300 nM), or DMSO 
(vehicle, 0.1%) was added to sEH and after 10 min at 4 °C, the reaction was started by addition of the substrate 
(50 µM PHOME) and stopped after 60 min before analyzing the fluorescent product. Data are expressed in 
percentage of control and are given as means ± S.E.M., n = 3–4, ***p < 0.001; vs vehicle (paired t-test). (b/c) 
sEH activity was analyzed in intact HepG2 cells and for recombinant sEH. Cells and enzyme were pre-incubated 
with DMSO (vehicle, 0.1%), diflapolin (indicated concentrations), SC57464A (0.3 µM), AUDA (5 µM) or 
MK886 (0.3 µM), and then incubated with 14,15-EET. Amounts of 14,15-EET and 14,15-DiHETrE were 
analyzed by UPLC-MS/MS. Data are expressed as percentage of control and are given as means ± S.E.M., n = 3, 
*p < 0.05; versus vehicle (paired t-test). (d) Phosphatase activity of sEH was analyzed in a fluorescence-based 
cell-free assay. Diflapolin or DMSO (vehicle, 0.1%) was added to human recombinant phosphatase domain 
of sEH for 10 min at 4 °C, the reaction was initiated by addition of DiFMUP (300 µM) and fluorescence was 
analyzed for 45 min. Data are expressed as percentage of vehicle control (100%), are given as means ± S.E.M., 
n = 3 *p < 0.05 vs. vehicle control (paired t-test). (e) Co-incubations of human recombinant 5-LOX and LTA4-H 
in PBS plus 1 mM EDTA pre-incubated with diflapolin (10 µM), AUDA (10 µM), SC57461A (0.3 µM), zileuton 
(3 µM), or vehicle (0.1% DMSO) for 10 min on ice and subsequently stimulated by 20 µM AA and CaCl2 for 
10 min at 37 °C. LTB4 isomers were analyzed by HPLC. Data are expressed as percentage of vehicle control 
(100%), are given as means ± S.E.M., n = 3–4. *p < 0.05 vs. vehicle control (paired t-test with logarithmized 
values).
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visualized by proximity-ligation assay (PLA) (Fig. 4), a common feature of FLAP inhibitors37. MK886 gave com-
parable effects, whereas the 5-LOX inhibitor zileuton failed in this respect.
Diflapolin exhibits potent anti-inflammatory properties in in-vivo experiments. We next inves-
tigated the anti-inflammatory effectiveness of diflapolin in the zymosan-induced peritonitis mouse model39 that 
is strongly related to the pathophysiological activities of LTs. Diflapolin pre-treatment (1, 3 and 10 mg/kg, i.p. 
30 min before zymosan injection) induced a significant reduction of LTC4 and LTB4 peritoneal levels, starting 
from the dose of 1 mg/kg (Fig. 5a and b) and comparable to the effect of MK886 (1 mg/kg, i.p. 30 min before 
zymosan). Since LTB4 is a major chemoattractant for leukocytes, diflapolin and MK886 caused concomitant block 
of leukocyte recruitment, which was dose-dependent for diflapolin (Fig. 5c). Accordingly, at the dose of 10 mg/kg, 
Figure 3. Diflapolin shows target specificity within the AA cascade without cytotoxicity. (a) mPGES-1 activity. 
Microsomes of IL-1β-stimulated A549 cells were pretreated with diflapolin, 10 µM MK886, or vehicle for 10 min 
on ice and stimulated with 20 µM PGH2. After 1 min at 4 °C, PGE2 formation was analyzed by HPLC. (b) LTC4S 
activity. Microsomes of LTC4S-expressing HEK293 cells were pretreated with diflapolin, MK886 (10 µM), or 
vehicle for 10 min on ice with subsequent addition of LTA4-methyl ester. After 10 min at 4 °C, LTC4-methyl 
ester was analyzed by UPLC-MS/MS. (c) COX-1/2 activity. In cell-free assays, purified ovine COX-1 and 
recombinant human COX-2 were pretreated with diflapolin (10 µM), indometacin (10 µM) or vehicle (0.1% 
DMSO) for 5 min on ice and stimulated with AA (5 and 2 µM for COX-1 and -2, respectively for 10 min at 
37 °C. 12-HHT was analyzed by HPLC. (d) Effect of diflapolin on 12- and 15-LOX. Intact neutrophils were pre-
incubated by diflapolin or vehicle (0.1% DMSO) and stimulated with 2.5 µM Ca2+-ionophore plus 20 µM AA for 
10 min at 37 °C. 12- and 15-HETE were determined by HPLC. (e) AA release. [3H]AA-labeled neutrophils were 
pretreated with diflapolin (1 µM), RSC-3388 (10 µM) or vehicle (0.1% DMSO) and stimulated by 2.5 µM Ca2+-
ionophore for 15 min. Radioactivity of the supernatant was analyzed by scintillation counting. (f) Cell viability 
assay. Monocytes were treated with diflapolin (10 µM), staurosporin (3 µM) or vehicle (0.3% DMSO) for 24 
and 48 h, respectively. Cell viability was determined by MTT assay. Data are expressed as percentage of control 
(100%), means + SEM, n = 3–5. *p < 0.05; **p < 0.005; ***p < 0.001 vs. vehicle control (paired t-test).
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diflapolin inhibited the activity of MPO, a typical marker protein for neutrophils to 52.8 ± 12.2% (mean ± SEM) 
vs. vehicle control and reduced vascular permeability to 55.7 ± 14.4% (mean ± SEM) vs. vehicle control (Table 1), 
compared to inhibitory effects of MK886 (1 and 3 mg/kg) to 58.5 ± 10.6% and 48.6 ± 3.2%, respectively.
Discussion
Our recent pharmacophore-based virtual screening campaign for dual FLAP/sEH inhibitors proposed diflapolin 
as most promising hit and novel chemotype targeting both FLAP and sEH15. Here, we disclose diflapolin as a 
potent, dual inhibitor of FLAP and sEH with marked anti-inflammatory efficacy in vivo and high target selectiv-
ity. Side-by-side studies of diflapolin with the “FLAP benchmark inhibitor” MK88640 revealed comparable poten-
cies for inhibition of 5-LOX product biosynthesis in human leukocytes in vitro, and about equal effectiveness in 
suppression of LT formation and inflammatory properties in vivo using murine zymosan-induced peritonitis 
models.
The identification of novel chemotypes as FLAP inhibitors is hampered due to the lack of distinct assays that 
unequivocally proof direct and functional interference of a given compound with FLAP23. Thus far, no enzymatic 
activity has been assigned to FLAP that can be exploited as read-out in FLAP inhibitor discovery approaches. 
Moreover, FLAP does not support 5-LOX activity in cell-free assays (e.g. homogenates)41. Nevertheless, FLAP 
is essential for LT biosynthesis in intact cells and in vivo, as reflected by results from various pharmacological 
approaches40 and from gene intervention using FLAP knock-out mice42. Experimental evidence suggests that 
FLAP operates as a 5-LOX helper protein for transforming AA to 5-HPETE and for dehydration of 5-HPETE 
to LTA429, 43. FLAP is able to bind AA26 and to stimulate conversion of AA and 5-HPETE by 5-LOX44, and along 
these lines AA or 5-HPETE were required for in situ 5-LOX/FLAP complex assembly at the nuclear membrane 
in activated cells37, 38. Together, it appears that FLAP binds released AA and/or de novo-formed 5-HPETE and 
transfers them to 5-LOX, thus permitting optimal access of 5-LOX towards its substrates.
In light of these facts, assignment of a small molecule as FLAP inhibitor requires certain characteristics, which 
are all fulfilled by diflapolin. First of all, diflapolin did not randomly emerge as 5-LOX product biosynthesis inhib-
itor but was identified in a target-directed screening campaign for dual FLAP/sEH inhibitors applying two inde-
pendently created ligand-based pharmacophore models15. Second, diflapolin potently inhibited LT biosynthesis 
Figure 4. Effect of diflapolin on 5-LOX subcellular redistribution and 5-LOX/FLAP interaction. Cells 
were pretreated with diflapolin (1 µM), MK886 (0.3 µM), zileuton (3 µM) or 0.1% DMSO for 15 min, and 
then stimulated with 2.5 µM Ca2+-ionophore A23187 for 10 min at 37 °C. Top panel: immunofluorescence 
microscopy was used to determine 5-LOX subcellular localization. Single images (top lane) show 5-LOX 
staining (red) and the overlay of 5-LOX (red) and FLAP (green) (middle lane). Results are representative for 100 
individual cells of three independent experiments. Lower panel: in situ PLA was applied to determine 5-LOX/
FLAP complex assembly in monocytes (lower panel) using antibodies against 5-LOX and FLAP. DAPI stains the 
nucleus (blue), and PLA signals by 5-LOX/FLAP complexes are stained in magenta. Results are representative 
for 100 individual cells of three independent experiments.
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only in intact leukocytes (without being cytotoxic or suppressing AA substrate release) but did not directly affect 
the activity of isolated human recombinant 5-LOX or 5-LOX in leukocyte homogenates. Third, ample supply of 
exogenous AA strongly reduced the potency of diflapolin in stimulated neutrophils and monocytes, compatible 
with the proposed competition between AA and FLAP inhibitors for binding to FLAP43. Fourth, diflapolin pre-
vented the agonist-induced 5-LOX/FLAP complex assembly at the nuclear membrane in monocytes, visualized 
by PLA27, 37, without blocking 5-LOX translocation to the nucleus. Finally, the most striking proof for diflapolin 
inhibiting 5-LOX product formation by acting on FLAP but not on 5-LOX, is deduced from the fact that diflapo-
lin suppresses cellular 5-LOX activity in 5-LOX-transfected HEK293 cells only when FLAP was co-expressed, 
while in cells devoid of FLAP, diflapolin failed in this respect. Note that these features of diflapolin were shared 
also with the FLAP inhibitor MK886 but not with the direct 5-LOX inhibitor zileuton (refs 27, 29, 37, 41 and 45 
and this study). In conclusion, diflapolin is a potent LT biosynthesis inhibitor that confers its activity via inhibi-
tion of FLAP.
Besides FLAP, diflapolin was identified as potential hit using pharmacophore models for sEH inhibitors15, and 
it potently inhibited the epoxide hydrolase activity of sEH in a cell-free assay (IC50 20 nM), while the phosphatase 
activity was not affected. In contrast, the epoxide hydrolase activity of LTA4-H was not affected by diflapolin, 
indicating specificity for sEH. Interference of diflapolin with sEH is not surprising since the urea moiety is a 
typical structural feature of sEH inhibitors that prevent the degradation of EETs12, 46. EETs formed from AA by 
CYP enzymes display anti-inflammatory and antihypertensive properties, maintain vascular homeostasis, and 
act generally cardio-protective20, 47. Among several EET degrading pathways, sEH metabolizes EETs to the cor-
responding dihydroxyeicosatrienoic acids (DiHETrE) with accompanied loss of health-promoting benefits20, 48. 
Accordingly, inhibition of sEH elevates EET levels leading to various beneficial effects. Little is known about the 
physiological role of the phosphatase activity, but an influence on the regulation of the endothelial nitric oxide 
synthase (eNOS) and NO-mediated effect on endothelial cells was suggested49.
Because FLAP is a member of the MAPEG family, other structurally-related MAPEG members such as 
mPGES-1 and LTC4S might be targeted by diflapolin as well, which is the case for the FLAP inhibitors MK86636, 50  
and BRP-18727 that interfere with all three of these proteins. Diflapolin had no impact on mPGES-1 and LTC4S 
activity up to 10 µM, suggesting target specificity within the MAPEG family. Moreover, other enzymes within the 
Figure 5. Effect of diflapolin on LTC4 and LTB4 formation, and cell recruitment in zymosan-induced 
peritonitis. Male mice (n = 6–19, each group) were treated i.p. with diflapolin, MK886 or vehicle, 30 min before 
before induction of zymosan-induced peritonitis. (a) LTC4 levels were analysed 30 min after zymosan injection 
by ELISA. (b) LTB4 formation and (c) cell infiltration were analysed 4 h after zymosan injection. *p < 0.05; 
**p < 0.01, ***p < 0.001 versus vehicle (Anova + Bonferroni).
vascular permeability myeloperoxidase activity
absorption 
(610 nm)
% of vehicle 
control U/mL
% of vehicle 
control
vehicle 0.623 ± 0.04 100 1.23 ± 0.13 100
diflapolin 
10 mg/kg 0.347 ± 0.09 55.7 ± 14.4 0.65 ± 0.15 52.8 ± 12.2
MK886 
1 mg/kg n.d. n.d. 0.72 ± 0.13 58.5 ± 10.6
MK886 
3 mg/kg 0.303 ± 0.02 48.6 ± 3.2 n.d. n.d.
Table 1. Effect of diflapolin on vascular permeability and myeloperoxidase (MPO) activity in zymosan-
induced peritonitis. Male mice (n = 5 for vascular permeability, n = 7 for MPO; each group) were treated 
i.p. with diflapolin, MK886, or vehicle, 30 min before induction of zymosan-induced peritonitis. Analysis of 
vascular permeability and MPO was performed 30 min and 4 h, respectively, after zymosan injection. Data are 
given means ± S.E.M, (vascular permeability n = 5; myeloperoxidase activity n = 7) *p < 0.05 versus vehicle 
(Anova + Bonferroni). n.d., not determined.
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AA cascade including COX-1/2, epoxide hydrolase activity of LTA4-H, 12-LOX and 15-LOXs were not inhibited 
by diflapolin. Interestingly, formation of 15-HETE in neutrophil incubations was concentration-dependently 
increased by diflapolin, which might be explained by AA shunting towards the 15-LOX pathway. This may pro-
mote the formation of anti-inflammatory and pro-resolving LMs such as lipoxins, resolvins and protectins51. 
A shift from biosynthesis of pro-inflammatory eicosanoids and other oxylipins towards anti-inflammatory and 
pro-resolving LMs would certainly strengthen the power of dual FLAP/sEH inhibitors. Additionally, even though 
comprehensive data are yet not available, it is reasonable to assume that epoxy-fatty acids derived from other 
polyunsaturated fatty acids confer anti-inflammatory properties.
The current development of LT biosynthesis inhibitors as therapeutics focusses on FLAP inhibitors23. Early 
representatives such as the indole MK88618 and the quinoline BAY X-100519 are highly effective in vitro but 
probably due to their high lipophilicity they suffered from strong plasma protein binding, competition with fatty 
acids and, as a consequence reduced activity in vivo17, 40. However, more advanced compounds including the 
MK886 follow-up GSK2190915, the tetrahydrofuran derivative AZD6642 and the oxadiazole-based BI665915 
are less prone to plasma protein binding with advantageous pharmacokinetics23. These compounds are under 
active development (some entered clinical trials), and they appear to have lower risks of side effects as compared 
to 5-LOX inhibitors40. Diflapolin is structurally unrelated to these above-mentioned chemotypes and represents 
the first FLAP inhibitor with a polar urea moiety (seemingly the pharmacophore for sEH interference) and high 
efficiency in vivo.
In order to evaluate the in vivo efficacy and anti-inflammatory potential of diflapolin, we utilized the 
zymosan-induced peritonitis mouse model that is well established as test system for studying LT biosynthesis 
in vivo39. Our data show that diflapolin is about equally effective as MK886 in reducing LTB4 and LTC4 levels 
in the peritoneal exudates with consequent biological functions. LTB4 is a potent chemotactic agent for neutro-
phils52 and in fact, neutrophil infiltration into the peritoneal cavity was strongly reduced by diflapolin. Cys-LTs 
mediate plasma extravasation53 and diflapolin significantly impaired vascular permeability during peritonitis. 
Conclusively, diflapolin potently inhibits LT formation in vivo connected with anti-inflammatory activity.
We speculate that dual inhibition of FLAP and sEH inhibitor may have synergistic anti-inflammatory and 
cardio-protective actions. Indeed, increased levels of EETs seem to be cardio-protective47 and FLAP was reported 
to be linked to certain cardiovascular diseases54. DMLs that block sEH and COX or sEH and 5-LOX are proposed 
to have improved anti-inflammatory activities over compounds that interfere with only one target enzyme12, 13, 21, 55. 
Such DMLs dually targeting sEH and FLAP are thus far unknown. Future studies addressing the pharmacological 
relevance of suppression of LTs with accompanied elevation of EETs may reveal potential benefit in the therapy of 
inflammatory and cardiovascular diseases.
Taken together, here we provide substantial evidence that diflapolin acts as potent dual FLAP/sEH inhibitor 
with high target specificity. The compound lacks acute cytotoxicity and efficiently suppresses LT biosynthesis 
in vivo connected with potent anti-inflammatory activity in a mouse model. Based on these features, diflapolin 
might be a valuable chemical tool for studying the biology of FLAP and sEH, particularly as synergizing targets, 
and may represent a useful lead for evaluation of the therapeutic potential of dual FLAP and sEH inhibition in 
inflammatory and cardiovascular disorders.
Materials and Methods
Materials. Diflapolin was obtained from Specs designated AQ-090/41740539 (Zoetermeer, Netherlands). 
Bovine serum albumin (BSA), EDTA, glutathione, saccharose, and Tris, AppliChem (Darmstadt, Germany); 
L-glutamine, BioChem GmbH (Karlsruhe, Germany); β-PGE2 and tritium-labeled [5,6,8,9,11,12,14,15-3H] labe-
led AA, Biotrend Chemicals GmbH (Köln, Germany); AA, PGB1, 3-phenyl-cyano(6-methoxy-2-naphthalenyl)
methyl ester-2-oxiraneacetic acid (PHOME), LTC4-d5-methyl ester, LTA4 methyl ester, COX isoenzymes, and 
MK886, Cayman Chemical (Biomol, Hamburg, Germany); acetonitrile, Dulbecco’s modified Eagle’s high glu-
cose medium with glutamine, geneticin, penicillin/streptomycin-solution and trypsin-EDTA, GE Healthcare Life 
Science (Freiburg, Germany); PGH2, Larodan Fine Chemicals (Stockholm, SWE); Alexa Fluor 488 goat anti-rab-
bit, Alexa Fluor 555 goat anti-mouse, hygromycin B, Lipofectamine LTX Reagent Plus, and non-immune goat 
serum and Sf-900™ II SFM, Invitrogen (Darmstadt, Germany). DMSO, Merck (Darmstadt, Germany); IL-1β, 
ReproTech (Hamburg, Germany); ATP, Roche (Mannheim, Germany); SDS, Roth GmbH (Karlsruhe, Germany); 
zileuton, Sequoia Research Products (Oxford, UK); Dulbecco’s Buffer Substance (PBS), SERVA Electrophoresis 
(Heidelberg, Germany); dithiothreitol and HPLC solvents, VWR (Darmstadt, Germany); Ca2+-ionophore 
A23187, dextrane, fetal calf serum (FCS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 
non-essential amino acids, RPMI 1640 Medium, phenylmethanesulfonyl fluoride, soybean trypsin inhibitor, 
lysozyme, leupeptin, fatty acid free BSA, Duolink detection reagents red, Duolink PLA probe anti-rabbit PLUS, 
Duolink PLA probe anti-mouse MINUS, ATP agarose, Duolink wash buffers as well as other chemicals were from 
Sigma-Aldrich (Taufkirchen, Germany).
Cell isolation and cell culture. Peripheral blood (University Hospital Jena, Germany) was collected 
from fasted healthy adult donors that were informed about the aim of the study and gave written consent. The 
protocols for experiments with neutrophils or monocytes were approved by the ethical commission of the 
Friedrich-Schiller-University Jena (approval number 4292-12/14). All methods were performed in accordance 
with the relevant guidelines and regulations. Leukocyte concentrates were obtained by centrifugation (4000 × g, 
20 min, 20 °C) of heparinized blood preparations. Neutrophils and monocytes were immediately isolated as 
described before56. In brief, leukocyte concentrates were subjected to dextran sedimentation and centrifuged 
on lymphocyte separation medium (LSM 1077, PAA, Coelbe, Germany). For isolation of pelleted neutrophils, 
remaining erythrocytes were removed by hypotonic lysis, washed twice with ice-cold PBS and resuspended in 
medium to a cell density described for the respective experiments. Monocytes were separated from peripheral 
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blood mononuclear cells (PBMC) by adherence to cell culture flasks (Greiner Bio-one, Nuertingen, Germany) 
for 1.5 h (37 °C, 5% CO2) in RPMI 1640 containing L-glutamine (1 mM), heat-inactivated FCS (10%), penicillin 
(100 U/mL) and streptomycin (100 µg/mL), followed by cell-scraping and resuspension in PBS.
HEK293 cells were cultured in monolayers (37 °C, 5% CO2) in DMEM containing FCS (10%), penicillin 
(100 U/mL) and streptomycin (100 µg/mL). HEK293 cell lines stably expressing 5-LOX with or without FLAP 
were selected using geneticin (400 µg/mL) with or without hygromycin (200 µg/mL), respectively, as previously 
described29. Transfection of HEK293 was performed using pcDNA3.1 plasmids and lipofectamine according to 
the manufacturer’s instructions (Invitrogen, Darmstadt, Germany).
Sf9 cells were cultured in monolayers at 27 °C in Sf-900 II SFM medium containing FCS (10%), penicillin 
(100 U/mL) and streptomycin (100 µg/mL).
HepG2 cells were cultured as monolayers in RPMI 1640 containing FCS (10%), penicillin (100 U/mL) and 
streptomycin (100 µg/mL) at 37 °C, 5% CO2.
Expression, purification and activity assay of human recombinant 5-LOX. Human recombi-
nant 5-LOX was expressed in E.coli BL21 transformed with pT3-5-LOX plasmid at 30 °C overnight as described 
before57. Cells were lysed in lysis buffer containing triethanolamine (50 mM, pH 8.0), EDTA (5 mM), phenyl-
methanesulfonyl fluoride (1 mM), soybean trypsin inhibitor (60 µg/mL), dithiothreitol (2 mM) and lysozyme 
(1 mg/mL) and homogenized by sonification (3 × 15 s). 5-LOX was purified from the 40,000 × g supernatant 
(20 min, 4 °C) using an ATP-agarose column and diluted with PBS buffer containing 1 mM EDTA. To determine 
5-LOX product formation, aliquots (0.5 µg purified 5-LOX in 1 mL PBS plus 1 mM EDTA) were pre-incubated 
with the test compounds or vehicle (0.1% DMSO) on ice for 15 min and then stimulated with 20 µM AA and 
CaCl2 (2 mM) for 10 min at 37 °C. The reaction was stopped with one volume of ice-cold methanol and 5-LOX 
products were analyzed by RP-HPLC as previously described58. Briefly, 530 µl acidified PBS and 200 ng of internal 
PGB1 standard were added and solid phase extraction using C18 RP-columns (100 mg, UCT, Bristol, PA, USA) 
was performed. After elution with methanol, samples were analyzed by RP-HPLC using a C-18 Radial-PAK col-
umn (Waters, Eschborn, Germany). Unless stated otherwise, 5-LOX products include all-trans-isomers of LTB4 
and 5-HpETE as well as its corresponding alcohol 5-HETE.
Determination of 5-LOX products in intact cells and corresponding homogenates. In order to 
examine 5-LOX product formation in intact human neutrophils and monocytes, freshly isolated cells were resus-
pended in PBS buffer containing 0.1% glucose and 1 mM CaCl2 (PGC buffer) to a final cell density of 5 × 106 or 
2 × 106, respectively. Cells were pre-incubated with the test compounds or vehicle (0.1% DMSO) at 37 °C for 
15 min prior to stimulation with 2.5 µM Ca2+-ionophore A23187 for 10 min (37 °C) with or without supplemen-
tation of the indicated concentrations of AA. 5-LOX product formation was stopped by addition of one volume 
of ice-cold methanol, samples were subjected to solid phase extraction after addition of 200 ng PGB1 as internal 
standard and 5-LOX products were analyzed by RP-HPLC as described above.
Determination of 5-LOX products in corresponding homogenates was performed by resuspending neutro-
phils (final density of 5 × 106 cells/mL) or monocytes (2 × 106 cells/mL) in PBS containing 1 mM EDTA and son-
icated on ice (3 × 15 s). Aliquots of homogenates were pre-incubated with the test compounds or vehicle (0.1% 
DMSO) on ice for 15 min and stimulated with 20 µM AA and CaCl2 (2 mM) at 37 °C for 10 min. 5-LOX product 
formation was assayed as described for intact cells above.
For analysis of 5-LOX product formation in HEK293 cells stably expressing 5-LOX with or without FLAP, 
cells were harvested by trypsinization, pelleted (1,200 rpm, 5 min, 4 °C) and resuspended in PGC buffer to a final 
concentration of 1 × 106 cells/mL. Aliquots were pre-incubated with test compounds or 0.1% DMSO for 15 min, 
respectively, and stimulated with 2.5 µM A23187 and 3 µM AA. After termination of the incubations by addition 
of one volume of ice-cold methanol, samples were subjected to solid phase extraction and analysis of 5-LOX 
products as described above.
Determination of LTA4 hydrolase activity. In order to determine the activity of LTA4-H, aliquots 
of human recombinant 5-LOX (0.5 µg) and 10 µg of human recombinant LTA4-H (kindly provided by Dr. E. 
Proschak, Goethe University, Frankfurt, Germany) were suspended in 1 mL PBS containing 1 mM EDTA and 
pre-incubated with test compounds or vehicle (0.1% DMSO) for 10 min on ice. The specific LTA4-H inhibitor 
SC57461A (0.3 µM) was used as reference drug. Subsequently, incubations were stimulated with 20 µM AA and 
2 mM CaCl2 for additional 10 min at 37 °C. The reaction was stopped by 1 volume ice-cold methanol, 530 µL acid-
ified PBS and 200 ng of PGB1 as internal standard were added and subjected to solid phase extraction. All LTB4 
isomers were analyzed by HPLC as described above.
Expression, purification and activity assays of human recombinant sEH. Human recombinant 
sEH was expressed and purified as reported before59. In brief, Sf9 cells were infected with a recombinant bac-
ulovirus (kindly provided by Dr. B. Hammock, University of California, Davis, CA). 72 hrs post-transfection, 
cells were pelleted and sonicated (3 × 10 sec at 4 °C) in lysis buffer containing NaHPO4 (50 mM, pH 8), NaCl 
(300 mM), glycerol (10%), EDTA (1 mM), phenylmethanesulfonyl fluoride (1 mM), leupeptin (10 µg/mL), 
and soybean trypsin inhibitor (60 µg/mL). Supernatants after centrifugation at 100,000 × g (60 min, 4 °C) 
were subjected to a benzylthio-sepharose-affinity chromatography in order to purify sEH by elution with 
4-fluorochalcone oxide in PBS containing DTT (1 mM) and EDTA (1 mM). Dialyzed and concentrated (Millipore 
Amicon-Ultra-15 centrifugal filter) enzyme solution was assayed for total protein with Bio-Rad protein detection 
kit (Bio-Rad Laboratories, Munich, Germany) and the epoxide hydrolase activity was determined by using a 
fluorescence-based assay as described before60. Briefly, sEH was diluted in Tris buffer (25 mM, pH 7) supple-
mented with BSA (0.1 mg/mL) to an appropriate enzyme concentration and pre-incubated with test compounds 
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or vehicle (0.1% DMSO) for 10 min at room temperature (RT). The reaction was started by addition of 50 µM 
3-phenyl-cyano(6-methoxy-2-naphthalenyl)methyl ester-2-oxiraneacetic acid (PHOME), a non-fluorescent 
compound that is enzymatically converted into fluorescent 6-methoxy-naphtaldehyde at RT. After 60 min, reac-
tions were stopped by ZnSO4 (200 mM) and fluorescence was detected (λem 465 nm, λex 330 nm) and potential 
fluorescence of test compounds was subtracted from the read-out, if required.
In order to analyze the phosphatase activity of sEH, a recently published assay61 was performed. In brief, 
purified sEH-phosphatase-domain was pre-incubated with test compounds or vehicle (0.1% DMSO), in acetate 
buffer (50 mM, pH 5.8) containing MgCl2 (10 mM) and Triton-X-100 (0.01%) for 30 min at RT prior to addition 
of 6,8-difluoro-4-methylumbelliferyl phosphate (DiFMUP, 300 µM). Phosphatase activity was assayed by meas-
urement of fluorescence (λex 360 nm, λem 450 nm) of the dephosphorylated DiFMU for 45 min at 37 °C.
Determination of 14,15-DiHETrE-formation in HepG2 cells and in a cell-free assay. To assay the 
activity of sEH in a cell-based model, HepG2 cells were harvested by trypsinization, pelleted (1,200 rpm, 5 min, 
4 °C) and resuspended in PGC buffer to a final concentration of 1.5 × 106 cells/mL. Cells were pre-incubated with 
test compounds or 0.1% DMSO at 37 °C for 15 min, and incubated with 1.5 µM 14,15-EET (Cayman Chemical, 
Biomol, Hamburg, Germany) for 30 min at 37 °C. After termination of the reactions with one volume of ice-cold 
methanol, 1.31 ng d8-5(S)-HETE and 1.36 ng d4-LTB4 (Cayman Chemical, Biomol, Hamburg, Germany) were 
added as internal standards and samples were subjected to solid phase extraction. Briefly, samples were acidi-
fied with four volumes of MilliQ water pH 3.5 containing PBS-HCl and subjected to Waters Sep-Pak® Vac 6cc 
columns (Waters, Milford, MA, USA), washed once with MilliQ and hexane, and eluted with methylformiate. 
The nitrogen-dried samples were dissolved in 50% methanol, and 14,15-DiHETrE formation was measured 
by UPLC-MS/MS using an Acquity™ UPLC system (Waters, Milford, MA, USA) and a QTRAP 5500 Mass 
Spectrometer (ABSciex, Darmstadt, Germany) equipped with a Turbo V™ Source and electrospray ioniza-
tion (ESI). In brief, lipid mediators were separated using a Sep-Pak C18 35 cc Vac Cartridge, 10 g Sorbent per 
Cartridge, 55–105 µm Particle Size, 10/pk (Waters, Milford, MA, USA) at 50 °C with a flow rate of 0.3 mL/min. 
MilliQ water (A) and methanol (B) both acidified with 0.1% acetic acid were used as solvents with an increasing 
percentage of B starting at 42% and ending with 86% at 12.5 min followed by isocratic elution at 98% B for another 
3 min. Analytes were detected by multiple reaction monitoring in the negative ion mode using the following 
transitions: 14,15-EET (m/z 319 → 219), 14,15-DiHETrE (m/z 337 → 207), d8-5(S)-HETE (m/z 327 → 116) and 
d4-LTB4 (m/z 339 → 197). Ion spray voltage was set to 4000 V, the heater temperature to 500 °C, the declustering 
potential to 50–80 eV, the entrance potential to 10 eV, the collision cell exit potential to 10–13 eV, collision ener-
gies of 10 eV, the spray gas pressure to 40 psi, medium collision gas and the curtain gas pressure to 35 psi.
In order to confirm the identity of detected metabolites, human recombinant sEH was diluted in 25 mM Tris 
buffer pH 7.0 to a final concentration of 0.3 µg/mL and pre-incubated with test compounds or 0.1% DMSO on ice 
for 15 min and stimulated with 14,15-EET (1.5 µM, 30 min, 37 °C). Extraction and detection of metabolites was 
performed as described for the cell-based assay.
Determination of microsomal PGE2 synthase activity. To perform the analysis of microsomal PGE2 
synthase (mPGES)-1 activity, microsomal preparations of A549 cells were obtained as described before62. Briefly, 
A549 cells were cultivated in DMEM medium containing FCS (2%) and IL-1β (2 ng/mL) for 72 h (37 °C, 5% 
CO2). Cells were harvested and resuspended in homogenization buffer consisting of potassium phosphate (0.1 M, 
pH 7.4), phenylmethanesulfonyl fluoride (1 mM), soybean trypsin inhibitor (60 µg/mL), leupeptin (1 µg/mL), 
glutathione (2.5 mM), and sucrose (250 mM). After freezing the cells in liquid nitrogen and sonication (3 × 20 s), 
a differential centrifugation at 10,000 g (10 min, 4 °C) and 174,000 × g (60 min, 4 °C) was performed and pellets 
were resuspended in homogenization buffer. To assay mPGES-1 activity, microsomes were diluted in potassium 
phosphate buffer (0.1 M, pH 7.4) with glutathione (2 mM) and pre-incubated with the test compounds or vehicle 
(0.1% DMSO) on ice for 15 min. After stimulation (1 min, 4 °C) with 20 µM PGH2 the reaction was terminated 
by addition of stop solution containing FeCl3 (40 mM), citric acid (80 mM), and 11β-PGE2 (10 µM as internal 
standard) and analyzed for PGE2 product formation by RP-HPLC as reported before62.
Determination of LTC4 synthase (LTC4S) activity. LTC4S activity was assayed by using microsomes 
of HEK293 cells stably expressing LTC4S, as previously published63. In brief, HEK293 expressing LTC4S were 
cultivated as described above and selected using geneticin (400 µg/mL). Isolation of microsomes was performed 
as described for mPGES-1 above and microsomes were diluted in potassium phosphate buffer (0.1 M, pH 7.4) 
with glutathione (5 mM) to a final concentration of 2.5 µg protein per mL. After pre-incubation with the test 
compounds or vehicle (2% DMSO) for 10 min at 4 °C, reactions were started by addition of 1 µM LTA4-methyl 
ester and stopped by addition of one volume of ice-cold methanol after 10 min of incubation at 4 °C. To determine 
enzyme activity, acidified PBS and d5-LTC4-methyl ester (5 ng) as internal standard were added prior solid phase 
extraction and LTC4-methyl ester formation was analyzed by UPLC-MS/MS as described63.
Determination of COX activity. COX activity was assayed by using purified ovine COX-1 and recom-
binant human COX-2, respectively. Enzymes were diluted in Tris buffer (100 mM, pH 8) supplemented with 
glutathione (5 mM), EDTA (100 µM) and hemoglobin (5 µM) to a final concentration of 50 U/mL (COX-1) or 
20 U/mL (COX-2) and pre-incubated with test compounds or vehicle (0.1% DMSO) for 5 min at RT. After 30 sec 
at 37 °C, reactions were started with 5 µM AA (COX-1) or 2 µM AA (COX-2) and stopped after 5 min at 37 °C 
by addition of one volume of ice-cold methanol. Solid phase extraction was performed as described above after 
addition of 200 ng of internal PGB1 standard and COX product formation was determined by analysis of 12-HHT 
formation as reported before64.
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Analysis of acute cytotoxicity. Acute cytotoxicity of the compounds was determined using freshly iso-
lated monocytes. Cells (0.2 × 106) per sample were seeded in 100 µL buffer on 96-well plates and treated with the 
test compounds and appropriate controls for 24 or 48 hrs (37 °C, 5% CO2). After addition of MTT (5 mg/mL) for 
2 h (37 °C, 5% CO2), cells were lysed by SDS treatment (10%, pH 4.5) for 16–20 hrs and formazan formation was 
determined by measurement of absorbance at 570 nm.
Determination of [3H]-labeled arachidonic acid release. Freshly isolated human neutrophils were 
resuspended in RPMI 1640 medium to a final cell density of 107 cells/mL and incubated with 0.5 µCi/mL of 
[3H]-labeled arachidonic acid ([3H]-AA), corresponding to a concentration of 5 nM of the fatty acid, for 2 hrs 
(37 °C, 5% CO2). Cells were washed twice to remove unincorporated [3H]-AA and resuspended in PBS containing 
glucose (0.1%), fatty acid-free BSA (2 mg/mL) and CaCl2 (1 mM). Aliquots of 107 cells were pre-incubated with 
the test compounds or vehicle (0.1% DMSO) at 37 °C for 10 min and stimulated with 2.5 µM A23187 for another 
10 min. The reaction was stopped on ice and cells were centrifuged at 1,200 rpm (10 min, 4 °C). The collected 
supernatants were combined with 2 mL of liquid scintillation counting solution (Rotiszint eco plus, Carl Roth, 
Karlsruhe, Germany) and assayed for radioactivity by scintillation counting (Micro Beta Trilux, Perkin Elmer, 
Waltham, MA).
Immunofluorescence microscopy (IF) and proximity ligation assay (PLA). In order to investigate 
cellular redistribution of 5-LOX and FLAP in monocytes, freshly isolated PBMC were seeded onto glass cov-
erslips in RPMI 1640 containing L-glutamine (1 mM), heat-inactivated FCS (10%), penicillin (100 U/mL) and 
streptomycin (100 µg/mL) for 1.5 hrs (37 °C, 5% CO2). Cells were washed twice with PBS and pre-incubated 
with test compounds or vehicle control (0.1% DMSO) in PGC buffer for 15 min (37 °C) prior to stimulation with 
A23187 (2.5 µM, 10 min, 37 °C). The incubations were stopped by paraformaldehyde fixation (4%, 20 min, RT) 
and cells were permeabilized using 100% ice-cold acetone (5 min, 4 °C). Blocking with non-immune goat serum 
(30 min, RT) was performed prior to overnight incubation (4 °C) with primary monoclonal-mouse-anti-5-LOX 
antibody (1:100 dilution, a generous gift from Dr. D. Steinhilber, Goethe University Frankfurt, Germany) and 
polyclonal-rabbit-anti-FLAP antibody (5 µg/mL, Abcam, Cambridge, UK). Incubation with fluorophore-labeled 
secondary Alexa Fluor 488 goat anti-rabbit (1:1000) and Alexa Fluor 555 goat anti-mouse (1:1000) was processed 
for 30 min in the dark at RT and nuclear DNA was stained with DAPI-containing ProLong diamond antifade 
mountant (Invitrogen, Darmstadt, Germany) on glass slides. Cells were visualized by a Zeiss Axiovert 200 M 
microscope, and a Plan Neofluar × 100/1.30 Oil (DIC III) objective (Carl Zeiss, Jena, Germany) and image acqui-
sition was performed using an AxioCam MR camera (Carl Zeiss).
In situ protein interaction of 5-LOX and FLAP was analyzed by proximity ligation assay as described 
before37 and referring to the manufacturer’s protocol65. In brief, freshly isolated monocytes were treated as 
described for IF above. Overnight incubations with primary antibodies were then treated for 1 h (37 °C) with 
oligonucleotide-labeled specific secondary antibodies (PLA probes anti-mouse MINUS and anti-rabbit PLUS). 
Formation of circled DNA sequences was induced by addition of ligase and oligonucleotide mixture (30 min at 
37 °C). Rolling-circle-amplification of newly generated DNA template was performed (90 min, 37 °C) including 
hybridization of fluorescently-labeled oligonucleotides within the formed DNA strands, resulting in visualization 
of protein-protein interactions recognized as magenta-stained dots. Nuclear DNA staining with DAPI and image 
acquisition was performed as described above. Overview images were obtained using a Plan Neofluar 40/1.30 Oil 
(DIC III) objective (Carl Zeiss).
Murine peritonitis model. The animal studies are reported in accordance with the ARRIVE guidelines for 
reporting animal research66. Male CD-1 mice (33–39 g, 8–9 weeks, Charles River Laboratories, Calco, Italy) were 
housed in a controlled environment (21 ± 2 °C) and provided with standard rodent chow and water ad libitum. 
Mice received a standard diet containing 5.7% fat, 18.9% protein and 57.3% carbohydrate (Global Diet 2018, 
ENVIGO, Italy). The fatty acid composition was according to Matias et al.67.
Prior to experiments, all mice were allowed to acclimate for 5 days and kept at 12 h light–dark schedule, in 
which experiments were performed during the light phase. Animal care was in compliance with Italian regula-
tions on protection of animals used for experimental and other scientific purpose (Ministerial Decree 116/92) 
and with the European Economic Community regulations (Official Journal of E.C. L 358/1 12/18/1986). Animal 
studies were approved by the local ethical committee of the University of Naples Federico II on 27 February 
2014 (approval number 2014/18760). Mice were treated with diflapolin (1, 3 or 10 mg/kg), MK886 (1 or 3 mg/
kg), zileuton (10 mg/kg) or vehicle (0.9% saline solution containing 2% DMSO), received as intraperitoneal (i.p.) 
injection, 30 min prior induction of peritonitis according to well-recognized experimental design for studying LT 
synthesis inhibitors in acute inflammation27. Zymosan (Sigma, Milan, Italy) was prepared and injected i.p. as a 
final suspension (2 mg/mL) in 0.9% saline solution after boiling, centrifugation and sonication. Peritoneal lavage 
(3 mL of cold PBS) was performed after CO2-euthanasia at indicated time points, followed by 60 sec of gentle 
manual massage. Two mL of exudates were collected and infiltrated cells were determined using a Burker cham-
ber and vital trypan blue staining. Pelleted samples (18,000 × g, 5 min, 4 °C) were frozen (−80 °C) and assayed for 
myeloperoxidase (MPO) activity (pellet) or LTC4 and LTB4 formation (supernatant), respectively.
MPO of neutrophils was examined as follows: pellets from exudates were resuspended in PBS (50 mM, pH 
6) containing 0.5% hexadecyltrimethyl-ammonium bromide and sonicated, followed by 3 freeze-thawing cycles 
and a final sonication. Supernatants of centrifuged samples (18,000 × g, 30 min) were added to a 96-well plate and 
reactions were initiated by addition of PBS (50 mM, pH 6) containing o-dianisidine (0.167 mg/mL) and hydrogen 
peroxide (0.0005%). Absorbance was monitored in the kinetic mode (Biorad Imark microplate) and levels of 
MPO were determined using a calibration curve with human neutrophils as reference standard. MPO levels were 
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expressed as units MPO per mouse. LTC4 and LTB4 formation within the supernatants were determined by EIA 
(Enzo Life Sciences International Inc., Lörrach, Germany) according to manufacturer’s protocol39.
Vascular permeability was assessed according to a previous report27. Briefly, 0.3 mL of 0.9% saline solution 
supplemented with Evans blue dye (40 mg/kg) was injected intravenously (i.v.) into the caudal vein followed by 
immediate peritonitis induction (using zymosan). After 30 min, peritoneal lavage exudates of CO2-euthanized 
were collected as described above. Absorbance of the centrifuged supernatants (3,000 × g, 5 min) was measured 
at 650 nm (Beckman Coulter DU730).
Statistics. Results are presented as mean ± standard error of the mean out of n independent experiments, 
where n represents the number of performed experiments on different days or with different donors or the num-
ber of animals for in vivo studies. IC50 values were calculated from at least 5 different concentrations using a 
nonlinear regression interpolation of semi-logarithmic graphs in GraphPad Prism (GraphPad Software Inc., 
San Diego, CA). Statistical evaluation was performed by one-way ANOVA using GraphPad InStat (Graphpad 
Software Inc., San Diego, CA) followed by a Bonferroni post-hoc test for multiple or student t-test for single com-
parisons, respectively. P-values < 0.05 were considered as significant.
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